/stocks — the workspaceLOADING

CRVS · All filings · Read this filing

What changed 10-K

Item 9A. Controls and Procedures

2026-03-12 compared with 2025-03-25 · 13 added, 33 removed, 148 unchanged (24% of the section changed)

7 unchanged sentences

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024, the end of the period covered by this Annual Report on Form 10-K.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025, the end of the period

covered by this Annual Report on Form 10-K.

Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

25 unchanged sentences

We have adopted an insider trading policy governing the purchase, sale and other dispositions of our securities by our directors, officers and employees that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable listing standards.

A copy of our insider trading policy is filed as Exhibit 19 to this Annual Report on Form 10-K.

A copy of our insider trading policy is incorporated by reference as Exhibit 19 to this Annual Report on Form 10-K.

Executive Compensation

19 unchanged sentences

Form of Common Stock Certificate.

Amended and Restated Investors’ Rights Agreement, dated September 16, 2015, by and among Corvus Pharmaceuticals, Inc.

and the investors listed therein.

Form of Warrant

Form of Pre-Funded Warrant

1 unchanged sentence

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Office Lease, dated as of January 27, 2015, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

First Amendment to Office Lease, dated as of March 19, 2015, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Second Amendment to Office Lease, dated as of August 20, 2015, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC

Third Amendment to Office Lease, dated as of June 27, 2016, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Fourth Amendment to Office Lease, dated as of August 15, 2016, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Fifth Amendment to Office Lease, dated as of March 2, 2018, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Sixth Amendment to Office Lease, dated as of April 5, 2018, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Seventh Amendment to Office Lease, dated as of October 11, 2018, by and between Corvus Pharmaceuticals, Inc.

and ARE-819/863 Mitten Road, LLC.

Eighth Amendment to Office Lease, dated as of September 13, 2021, by and between Corvus Pharmaceuticals, Inc.

and ARE 819/863 Mitten Road, LLC .

Sublease agreement, dated August 1, 2021, by and between Corvus Pharmaceuticals, Inc.

and Angel Pharmaceuticals US Inc.

Sub-Sublease agreement, dated as of October 22, 2024, by and between Corvus Pharmaceuticals, Inc.

3 unchanged sentences

Amendment to the 2014 Equity Incentive Plan, dated July 24, 2015.

Incorporated by Reference

Exhibit Description

Amendment to the 2014 Equity Incentive Plan, dated September 14, 2015.

20 unchanged sentences

2016 Employee Stock Purchase Plan.

Incorporated by Reference

Exhibit Description

Non-Employee Director Compensation Program.

10 unchanged sentences

and Jefferies LLC.

Incorporated by Reference

Exhibit Description

Securities Purchase Agreement, dated May 1, 2024, between the Company and the Investors.

17 unchanged sentences

# Indicates management contract or compensatory plan.

** The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals, Inc.

** The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed

with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals, Inc.

under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.

22 unchanged sentences

March 12, 2026

/s/ TERRY GOULD

March 25, 2025

(Terry) Gould III

GRAIS, M.D., J.D.

1 unchanged sentence

Grais, M.D., J.D.

/s/ DAVID MOORE

March 12, 2026

March 12, 2026

/s/ PETER THOMPSON, M.D.

1 unchanged sentence

Peter Thompson, M.D.

/s/ RICHARD A.

VAN DEN BROEK

March 12, 2026

van den Broek

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.